The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
A phase 2 trial of neoadjuvant futibatinib plus durvalumab for cisplatin-ineligible patients with FGFR overexpressing muscle-invasive bladder cancer.
 
Yuanquan Yang
Stock and Other Ownership Interests - Pfizer
Consulting or Advisory Role - Exelixis; The whiteoak group; Xencor
Speakers' Bureau - AstraZeneca
Research Funding - Amgen (Inst); Incyte (Inst); Novartis (Inst); Recordati (Inst); Xencor (Inst)
 
Rohit Jain
Honoraria - Curio Science; DAVA Oncology; FLASCO; MJH Life Sciences
Consulting or Advisory Role - AVEO; Bristol-Myers Squibb; EMD Serono; Gilead Sciences; Sanofi
Research Funding - Bristol Myers Squibb; Gilead Sciences; NCI
Travel, Accommodations, Expenses - Bristol Myers Squibb Foundation; DAVA Oncology; FLASCO; Sanofi
 
Shilpa Gupta
Stock and Other Ownership Interests - BioNTech SE; Moderna Therapeutics; Nektar
Consulting or Advisory Role - Astellas Pharma; Bayer; Bristol-Myers Squibb/Medarex; EMD Serono; Foundation Medicine; Genzyme; Gilead Sciences; Merck; Natera; Pfizer; Seagen
Speakers' Bureau - Bristol-Myers Squibb; Gilead Sciences; Seagen
Research Funding - Bristol Myers Squibb Foundation (Inst); EMD Serono (Inst); Exelixis (Inst); Gilead Sciences (Inst); Merck (Inst); Moderna Therapeutics (Inst); Novartis (Inst); QED Therapeutics (Inst); Roche/Genentech (Inst); Seagen (Inst)
Patents, Royalties, Other Intellectual Property - UpToDate author royalty
Travel, Accommodations, Expenses - Pfizer
 
Irene Tsung
No Relationships to Disclose
 
Dharmesh Gopalakrishnan
No Relationships to Disclose
 
Jinesh Gheeya
No Relationships to Disclose
 
Lai Wei
No Relationships to Disclose
 
Swati Satturwar
No Relationships to Disclose
 
Anil Parwani
No Relationships to Disclose
 
Katharine Collier
No Relationships to Disclose
 
Kamal Pohar
No Relationships to Disclose
 
Debasish Sundi
No Relationships to Disclose
 
Cheryl Lee
No Relationships to Disclose
 
Zihai Li
No Relationships to Disclose
 
Sameek Roychowdhury
Stock and Other Ownership Interests - Johnson & Johnson (I)
Honoraria - Illumina; Integrated DNA Technologies
Consulting or Advisory Role - AbbVie; Incyte; Incyte; Merck; QED Therapeutics; Seagen
Research Funding - Ignyta; Incyte; QED Therapeutics; Takeda
 
Amir Mortazavi
Consulting or Advisory Role - Targeted Oncology
Research Funding - Astellas Pharma (Inst); Bristol-Myers Squibb (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Merck (Inst); Novartis (Inst); Seagen (Inst)